BP563

(±)-Vigabatrin

British Pharmacopoeia (BP) Reference Standard

• 别名: (R,S)-4-氨基-5-己烯酸, (±)-γ-乙烯基-GABA, (±)-4-氨基己酸
• 经验公式（希尔记法）: C₆H₁₁NO₂
• CAS号: 68506-86-5
• 分子量: 129.16
• MDL號碼: MFCD00274577
• 分類程式碼代碼: 41116107
• NACRES: NA.24

属性

• 等級: pharmaceutical primary standard
• API 家族: vigabatrin
• 形狀: solid
• 儲存期限: limited shelf life, expiry date on the label
• 製造商／商標名: BP
• 應用: pharmaceutical; pharmaceutical small molecule
• 格式: neat
• 儲存溫度: 2-8°C
• SMILES 字串: NC(CCC(O)=O)C=C
• InChI: 1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)
• InChI 密鑰: PJDFLNIOAUIZSL-UHFFFAOYSA-N
• 基因資訊: human ... ABAT(18)

说明

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Vigabatrin BP Reference standard, intended for use in laboratory tests only as specifically prescribed in the British Pharmacopoeia.

Also used in monographs such as:

Vigabatrin Tablets

Vigabatrin Oral Powder

Gabapentin Oral Solution

生化／生理作用

不可逆的 GABA 转氨酶抑制剂。增加神经末梢的胞内 GABA 浓度；具有抗癫痫活性。

包裝

Unit quantity: 150 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia

其他說明

Sales restrictions may apply.

安全信息

• 象形圖: GHS08
• 訊號詞: Danger
• 危險聲明: H372
• 防範說明: P260 - P264 - P270 - P314 - P501
• 危險分類: STOT RE 1
• 標靶器官: Eyes,Central nervous system
• 儲存類別代碼: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• 水污染物質分類（WGK）: WGK 1
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable